

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**ZJ**

**中基長壽科學**

ZHONG JI LONGEVITY SCIENCE

**Zhong Ji Longevity Science Group Limited**

**中基長壽科學集團有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 767)**

## **VOLUNTARY ANNOUNCEMENT**

### **ENTERING INTO OF A COMMODITY SUPPLY CONTRACT WITH SINOPHARM HOLDINGS HUBEI GUODA PHARMACY CO., LTD.**

This announcement is made by Zhong Ji Longevity Science Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company is pleased to announce that on 6 April 2022, Shenzhen Zhong Ji Health Science Company Limited\* (深圳市中基健康科學有限公司) (“**Zhong Ji Health**”), a wholly-owned subsidiary of the Company, signed a commodity supply contract (the “**Supply Contract**”) with Sinopharm Holdings Hubei Guoda Pharmacy Co., Ltd. (“**Hubei Sinopharm**”). The signing of the Supply Contract marks the formal formation of a strategic partnership between the two parties, which is the first step of the Group’s retail coverage in Mainland China after obtaining the legal rights to distribute ZJ1 VC Extended-Release Tablets, a biological product from the United States, on the Mainland. The Group’s next endeavour is continuously enhancing the development and collaboration with the top 100 offline pharmaceutical retailers in China, with a view to developing a more convenient physical channel for the public.

#### **INFORMATION ABOUT HUBEI SINOPHARM**

China National Pharmaceutical Group Co., Ltd. (“**CNPGC**”) is the largest pharmaceutical and healthcare industry group with the most comprehensive industrial chain and the strongest integrated strength in China, ranking 109th among the US Fortune Global top 500 enterprises in 2021.

Hubei Sinopharm is the core enterprise of CNPGC in Hubei, with nearly 200 retail pharmacies, including more than 50 self-managed retail outlets in Wuhan and more than 100 in surrounding cities. The company currently hires more than 500 employees in the city, which is among the largest in the drug retail industry in terms of business scale.

## **REASONS FOR AND BENEFITS OF ENTERING INTO THE SUPPLY CONTRACT**

The Board believes that on the basis of this strategic agreement, the Company will leverage Hubei Sinopharm's comprehensive, resourceful and multi-dimensional model for their marketing channels to establish retail channels of pharmaceuticals with broad and thorough coverage, further improving the Group's layout in the field of longevity science.

By order of the Board  
**Zhong Ji Longevity Science Group Limited**  
**Yan Li**  
*Chairman*

Hong Kong, 7 April 2022

As at the date of this announcement, the Directors are:

*Executive Directors*

Mr. Yan Li (*Chairman*)  
Mr. Li Jiuhua (*Chief Executive Officer*)  
Mr. Li Xiaoshuang  
Ms. Cao Xie Qiong

*Independent non-executive Directors*

Mr. Tam Ho Leung Simon  
Ms. Wang Weixia  
Mr. Chai Nan  
Mr. Lee See Barry

*Non-executive Directors*

Dr. He Yiwu  
Ms. Choi Ngai Wah

*In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.*

\* *For identification purposes only*